Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
Bioequivalence clinical trial of two formulations of ezetimibe/atorvastatin
Laboratorios Tillomed Spain S.L.U
Healthy volunteers
1 trial -
Bioequivalence clinical trial of two formulations of linagliptin
Laboratorios Tillomed Spain S.L.U
Healthy volunteers
1 trial -
Bioequivalence clinical trial of two formulations of linagliptin
Laboratorios Tillomed Spain S.L.U
Healthy volunteers
1 trial -
Bioequivalence clinical trial of two formulations of linagliptin/metformin.
Laboratorios Tillomed Spain S.L.U
Healthy volunteers
1 trial -
Bioequivalence clinical trial of two formulations of loperamide.
Laboratorios Tillomed Spain S.L.U
Healthy volunteers
1 trial -
Bioequivalence clinical trial of two formulations of loperamide.
Laboratorios Tillomed Spain S.L.U
Healthy volunteers
1 trial -
Bioequivalence clinical trial of two formulations of loperamide.
Laboratorios Tillomed Spain S.L.U
Healthy volunteers
1 trial -
Bioequivalence clinical trial of two formulations of loperamide.
Laboratorios Tillomed Spain S.L.U
Healthy volunteers
1 trial -
Bioequivalence clinical trial of two formulations of rosuvastatin.
Laboratorios Tillomed Spain S.L.U
Hypercholesterolemia
1 trial -
Bioequivalence clinical trial of two formulations of vortioxetine.
Laboratorios Tillomed Spain S.L.U
Healthy volunteers
1 trial -
Bioequivalence of Amoxicillin and Clavulanic Acid 250 mg/62.5 mg/5 mL Powder for Oral Suspension versus Augmentin® Forte 250 mg/62.5 mg/5 mL Powder for Oral Suspension in Healthy Participants Under Fed Conditions
BIAL - Portela & Ca
No medical condition.
1 trial -
Bioequivalence of Amoxicillin and Clavulanic Acid 500 mg/125 mg Film-Coated Tablets in Healthy Participants Under Fed Conditions.
BIAL - Portela & Ca
No medical condition.
1 trial -
Bioequivalence of Amoxicillin and Clavulanic Acid 875 mg/125 mg Film-Coated Tablets in Healthy Participants Under Fed Conditions.
BIAL - Portela & Ca
No medical condition.
1 trial -
Bioequivalence of Apixaban 5 mg Film-Coated Tablets in Healthy Subjects Under Fasting Conditions.
Laboratorios Tillomed Spain S.L.U
No medical condition.
1 trial -
Bioequivalence of Calcifediol monohydrate 0.266 mg Soft Capsules in Healthy Participants Under Fasting Conditions.
Laboratorios Tillomed Spain S.L.U
No medical condition.
1 trial -
Bioequivalence of Cladribine 10 mg from two different products
Lacuna Pharma Pty Ltd
No therapeutic indication in the current trial with healthy volunteers. The intended indication is for treatment of adult patients with highly active relapsing multiple sclerosis (MS).
1 trial -
Bioequivalence of Etonogestrel 68 mg Implant in Healthy Pre-Menopausal, Non-Pregnant Female Participants.
Laboratorios Tillomed Spain S.L.U
No medical condition.
1 trial -
Bioequivalence of Etonogestrel 68 mg Implant in Healthy Pre-Menopausal, Non-Pregnant Female Participants.
Laboratorios Tillomed Spain S.L.U
No medical condition
1 trial -
Bioequivalence of Lenvatinib 10 mg Capsules in Healthy Participants Under Fasting Conditions
Lacuna Pharma Pty Ltd
No medical condition
1 trial -
Bioequivalence of Lenvatinib 10 mg Capsules versus Lenvima® 10 mg Capsules in Healthy Participants Under Fasting Conditions.
Lacuna Pharma Pty Ltd
No medical condition.
1 trial -
Bioequivalence of Lenvatinib 10 mg Capsules versus Lenvima® 10 mg Capsules in Healthy Participants Under Fasting Conditions.
Lacuna Pharma Pty Ltd
No medical condition.
1 trial -
Bioequivalence of Lenvatinib 10 mg Capsules versus Lenvima® 10 mg Capsules in Healthy Participants Under Fed Conditions
Lacuna Pharma Pty Ltd
No medical condition
1 trial -
Bioequivalence of Lisdexamfetamine dimesylate 10 mg Capsules in Healthy Participants Under Fasting Conditions.
Lacuna Pharma Pty Ltd
No medical condition.
1 trial -
Bioequivalence of Lisdexamfetamine dimesylate 10 mg/mL Oral Solution in Healthy Participants Under Fasting Conditions.
Lacuna Pharma Pty Ltd
No medical condition.
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources